# A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept

> **NCT07419178** · NA · RECRUITING · sponsor: **Azienda Ospedaliero-Universitaria di Parma** · enrollment: 265 (estimated)

## Conditions studied

- Myelofibrosis (MF)

## Interventions

- **DIAGNOSTIC_TEST:** Diagnosis of MPN subtypes

## Key facts

- **NCT ID:** NCT07419178
- **Lead sponsor:** Azienda Ospedaliero-Universitaria di Parma
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-05
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-04-30
- **Target enrollment:** 265 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07419178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07419178, "A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07419178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*